NATURECELL CO.,LTD.
Financials
Valuation Metrics
NATURECELL CO.,LTD.'s Market Cap is ₩1.6T. At end of 2025 it was ₩1.4T. Ranked #245 of 2,421 in KR market (top 10%), #57 of 1,640 on KOSDAQ (top 3%), #23 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 10%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.59T KRW | KR#245/2,421 Sec#23/231 |
| Revenue | 20.51B KRW | KR#2,132/2,421 Sec#155/231 |
| Net Income | -2.71B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 88.56B KRW | KR#1,873/2,421 Sec#150/231 |
| Net Assets | 62.94B KRW | KR#1,757/2,421 Sec#148/231 |
| Employees | 91 | KR#1,713/2,421 Sec#135/231 |
| Value | ||
| P/B | 25.23x | KR#2,404/2,421 Sec#225/231 |
| P/S | 77.45x | KR#2,384/2,421 Sec#204/231 |
| FCF Yield | -1.03% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -4.31% | KR#1,773/2,421 Sec#126/231 |
| ROA | -3.06% | KR#1,832/2,421 Sec#130/231 |
| Op. Margin | -17.93% | KR#2,099/2,421 Sec#142/231 |
| Revenue Growth | -14.91% | KR#2,033/2,421 Sec#185/231 |
| Financial Health | ||
| Debt Ratio | 40.69% | KR#808/2,421 Sec#94/231 |
| Total Debt | 17.00B KRW | KR#1,436/2,421 Sec#119/231 |
| FCF | -16.39B KRW | KR#1,842/2,421 Sec#172/231 |
| Cash | 21.29B KRW | KR#1,215/2,421 Sec#87/231 |
| Current Ratio | 1.76x | KR#994/2,421 Sec#111/231 |
| Performance | ||
| 1Y Return | 16.82% | KR#475/2,421 Sec#31/231 |
| 1M Return | 9.31% | KR#515/2,421 Sec#36/231 |
| From 52W High | -33.29% | KR#650/2,421 Sec#39/231 |
| 1Y MDD | -41.22% | KR#630/2,421 Sec#45/231 |
| Trading | ||
| Volume | 92,690 shares | KR#817/2,421 Sec#75/231 |
| Trading Value | 2.29B KRW | KR#526/2,421 Sec#48/231 |
| Foreign Own. | 7.37% | KR#606/2,421 Sec#50/231 |
| Per Share | ||
| EPS | -42 KRW | KR—/2,421 Sec—/231 |
| BPS | 977 KRW | KR#2,310/2,421 Sec#212/231 |
Company Info
Established in 1971 and listed on KOSDAQ in 1992, the company changed its corporate name to Naturecell Co., Ltd. in 2013, and acquired 100% of Naturecell America in the US in 2022, incorporating it as a subsidiary. It focuses on the R&D and commercialization of treatments for rare and intractable diseases using autologous fat-derived stem cells, conducting overseas clinical trials. Additionally, it manufactures and sells stem cell culture medium cosmetics and vegan beverages. Naturecell is headquartered in Yeongdeungpo-gu, Seoul.